|
|
Article: StemCyte Expands Support of World Renowned Spinal Cord Injury Researcher Through Agreement with Rutgers University.
- Article from:
- PR Newswire
- Article date:
- February 26, 2008
|
Copyright informationCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
StemCyte, Rutgers Sign Research, Licensing Agreement for Novel Human Umbilical Cord Blood Treatment for Spinal Cord Injury Being Developed by Wise Young, M.D., Ph.D.
NEW YORK, Feb. 26 /PRNewswire/ -- StemCyte Inc. and Rutgers, The State University of New Jersey, today announced at the Stem Cell Summit that they have entered into a research and licensing agreement for a spinal cord injury therapy being developed by Wise Young, M.D., Ph.D., that uses StemCyte's proprietary human umbilical cord blood (UCB) stem cells in conjunction with lithium.
Under the terms of the agreement, StemCyte will provide financial sponsorship for Dr. Young's work at Rutgers' W.M. Keck Center ...